Ltroz Tablet USP

Ltroz Tablet USP Specification

Packaging Type
Blister pack

Brand Name
Ltroz

Salt Composition
Letrozole 2.5 mg

Life Span
24 months

Pacakaging (Quantity Per Box)
5 x 5 Tablets

Dosage Form
Oral tablet

Indication
Adjuvant or metastatic breast cancer in postmenopausal women

Drug Type
General Medicines

Ingredients
Letrozole USP 2.5 mg

Physical Form
Tablets

Function
Breast cancer treatment (aromatase inhibitor)

Recommended For
Women with breast cancer (postmenopausal)

Dosage
As directed by the physician

Dosage Guidelines
As per the doctor's advice

Suitable For
Adults (Postmenopausal women)

Quantity
At per requirement

Storage Instructions
Keep at cool and Dry Place

Regulatory Approval
WHO-GMP certified manufacturing facility

Color
Yellow

Usage
Hormonal therapy for hormone receptor-positive breast cancer

Shelf Life
2 years

Shape
Round

Markings
LT02 imprint

Prescription/Non Prescription
Prescription

Ltroz Tablet USP Trade Information

Minimum Order Quantity
100 Strips

Supply Ability
5000 Strips Per Month

Delivery Time
7 Days

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

About Ltroz Tablet USP

Reduced price, triumphant results-Ltroz Tablet USP is an illustrious hormonal therapy designed specifically for postmenopausal women battling hormone receptor-positive breast cancer. Each yellow, round tablet is imprinted with LT02 and delivers superior efficacy with Letrozole 2.5 mg. WHO-GMP certified, it is suitable for both adjuvant and metastatic contexts, reflecting a commitment to both quality and safety. Explore the assurance of a reliable, prescription-only treatment backed by a 2-year shelf life. Ltroz is distributed in efficient blister packaging, ensuring optimal preservation and convenience.

Ltroz Tablet USP: Application and Therapeutic Uses

Ltroz Tablet USP is indicated for use in adults, specifically postmenopausal women, as an adjuvant or metastatic breast cancer therapy. Its application surface is oral, via easy-to-swallow round tablets. Commonly used in hospital settings, its application media covers hormone receptor-positive cases, leveraging Letrozole 2.5 mg as an aromatase inhibitor. Ltroz plays a vital role in the treatment protocol for breast cancer, supporting healthcare providers in delivering effective, targeted hormonal therapy.

Packaging, Valuation, and Export Market Overview

Ltroz Tablet USP is securely packed in blister strips, each consisting of 5 tablets, with 5 strips per export-oriented box. This ensures reduced expenditure on spoilage and improved shelf longevity-valued at 24 months. Serving the global export market from India, the product comes with a sample policy designed for interested buyers, simplifying the initial valuation process. Its superior supply ability supports large-scale wholesaling, addressing the demand for cost-effective, quality-assured cancer therapies.

Specification

Packaging Type	5 Stripe in one box
Brand	Letroz
Form	Tablet
Prescription/Non prescription	Prescription
Treatment	Breast Cancer
Dose/Strength (ex. 1 mg or 1 ml)	2.5 mg
Manufacturer	Intas Pharmaceuticals
Composition	Letrozole
Usage/Application	Hospital
Packaging Size	5 Tablet in 1 strip

FAQ's of Ltroz Tablet USP:

Q: How should Ltroz Tablet USP be consumed for optimal results?

A: Ltroz Tablet USP should be taken orally, as directed by your physician. Adherence to the prescribed dosage and schedule is essential for optimal therapeutic benefit.

Q: What conditions is Ltroz Tablet USP prescribed for?

A: Ltroz Tablet USP is primarily prescribed for hormone receptor-positive breast cancer in postmenopausal women, both in adjuvant and metastatic cases.

Q: Where is Ltroz Tablet USP manufactured and does it meet quality standards?

A: Ltroz Tablet USP is manufactured in India at a WHO-GMP certified facility, ensuring compliance with superior international quality and safety norms.

Q: When is Ltroz Tablet USP considered appropriate for a patient?

A: This medication is appropriate for postmenopausal women diagnosed with hormone receptor-positive breast cancer, following medical assessment and prescription.

Q: What are the distinguishing physical characteristics of Ltroz Tablet USP?

A: Ltroz Tablet USP comes as yellow, round tablets with an LT02 imprint, contained in blister packs to preserve quality throughout its 2-year shelf life.

Q: How does Ltroz Tablet USP benefit patients as part of hormonal therapy?

A: Ltroz Tablet USP inhibits aromatase, effectively reducing estrogen production, which is beneficial in slowing or stopping hormone-dependent tumor growth in breast cancer.